About Septal Solutions
Septal Solutions is developing a catheter system for hypertrophic cardiomyopathy. In this heart condition, a thickened septum, the muscle wall inside the heart, partly blocks blood leaving the left ventricle. The device reaches the heart through a blood vessel at the top of the leg. The device is built to hold itself in place and control the cut, so the procedure is fast and repeatable. The device is not approved by the U.S. Food and Drug Administration.
Septal Solutions is based in Exton, Pennsylvania. It was previously called Excision Medical, and under that name it worked on a system to remove leaflets from failing aortic heart valves. Greg Walters is co-founder, president and CEO. He founded Essential Medical, which Teleflex bought in 2018. The board includes Dr. David Wood, head of cardiology at Vancouver General Hospital.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 16, 2026 | Oct 27, 2026 | $7,319,695of $10.0M target | 29 | $252K | "Simple Agreement for Future Equity (SAFE)"Rule 506(b) | Form D ↗ |
| Sep 19, 2024 | Sep 27, 2024amended Nov 7, 2024 | $10,937,701of $11.0M target | 57 | $191K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 18, 2020 | Jul 8, 2024 | $410,000of $2.5M target | 9 | $45,556 | EquityRule 506(b) | Form D ↗ |
| Dec 4, 2023 | May 28, 2024 | $1,982,769of $2.0M target | 19 | $104K | EquityRule 506(b) | Form D ↗ |
| Mar 17, 2023 | May 28, 2024 | $2,996,837of $3.0M target | 20 | $149K | EquityRule 506(b) | Form D ↗ |
| Feb 23, 2022 | Dec 8, 2022 | $1,914,319of $2.5M target | 29 | $66,011 | EquityRule 506(b) | Form D ↗ |
| Total, six offerings | $25,561,321 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Septal Solutions
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Sep 15, 2022 | Funding | $2.5M | the company's internal team (lead) | Press release ↗ |
Why Investors Backed Septal Solutions
Septal Solutions is developing a catheter device for hypertrophic cardiomyopathy. The company's case is that this heart condition has few accessible treatment options. Its chief executive, Greg Walters, co-founded Essential Medical, which Teleflex bought in 2018. Ben Franklin Technology Partners of Southeastern Pennsylvania lists the company, then called Excision Medical, in its portfolio. The device is still in development and is not approved by the FDA.
The problem it targets
In hypertrophic cardiomyopathy, the heart muscle thickens. In some patients, the thickened septum, the wall between the heart's lower chambers, partly blocks blood flowing from the left ventricle to the aorta. Septal Solutions' case is that few accessible treatment options exist for these patients. It aims to bridge the gap between surgery and drugs.
What the product does
The company's Myotomy Solution is a catheter system that reaches the heart through a blood vessel at the top of the leg. The device builds on the proven effectiveness of cutting the thickened septum. It is designed to position and hold itself and to control the cut, so the procedure is fast and repeatable. The company is a development stage company, and the device is not approved by the FDA.
Progress so far
The company has no approved product, and its website reports no sales or customers. It had 19 jobs in 2024, nine of them new, according to Ben Franklin Technology Partners' impact report. In a November 2024 release, its landlord, Hankin Group, said the company had moved its headquarters to a 12,276 square foot space in Exton. Hankin also said the company was preparing to move from research to clinical testing.
Who backs it
Ben Franklin Technology Partners of Southeastern Pennsylvania lists the company, then named Excision Medical, among its healthcare portfolio highlights for 2024. In September 2022, the company raised $2.5 million, led by its internal team. Hankin Group's November 2024 release says the company had closed an $11 million Series A. The release does not name the investors. The company's board includes Greg Walters, Dr. David Wood, Michael Wallace, Jason Keiser and Grant Conway.
How the market is moving
Drugs for obstructive hypertrophic cardiomyopathy, the form in which the thickened septum blocks blood flow, are now on the market. Bristol Myers Squibb's Camzyos (mavacamten) is approved for symptomatic cases. On September 30, 2026, the FDA widened that approval to children weighing at least 30 kilograms (66 pounds). Cytokinetics won approval for a second drug, Myqorzo (aficamten), in December 2025, according to Pharmacy Times.
We wrote this summary from public statements by Septal Solutions and its investors. It is not investment advice.
Septal Solutions in the News
Leadership Team
Executive officers and directors listed on Septal Solutions's Form D filed Oct 27, 2026.
Earlier filings also listed Jason Keiser (secretary and treasurer, director, last listed Nov 2024) and Gary Roubin (director, last listed Nov 2024).
Sources
- SECSeptal Solutions, Inc. Form D, filed Sep 27, 2024
- SECSeptal Solutions, Inc. filing history
- Company siteAbout page (mission, vision, team, board of directors)
- Company siteTechnology page (septal myotomy, development stage, not FDA approved)
- Company siteContact page (260 Sierra Drive, Suite 120, Exton, PA)
- Company sitePrivacy policy (names Septal Solutions, Inc. and the Exton address)
- Investor siteBen Franklin Technology Partners of Southeastern Pennsylvania, 2024 Impact Report (lists Excision Medical)
- Press releaseTeleflex, 2018-10-04: Teleflex acquires Essential Medical (names Greg Walters and Dr. Gary Roubin as founders)
- Employer siteVCH Research Institute, 2025-10-22: Dr. David A. Wood appointed chief scientific officer of the Dilawri Cardiovascular Institute
- Other company siteFluid Biomed: bio of Michael P. Wallace (DeVoro Medical sold to Boston Scientific in 2021)
- Press releaseBristol Myers Squibb, 2026-09-30: FDA approves expanded Camzyos indication
- PressPharmacy Times, 2025-12-22: Aficamten (Myqorzo) receives FDA approval for obstructive hypertrophic cardiomyopathy